Skip to main content
. 2022 Sep 21;11(1):2147–2159. doi: 10.1080/22221751.2022.2114852

Figure 5.

Figure 5.

Seroreactivity to NGP28b of TL patients, before and after treatment. Sera from CL (n = 17) or ML (n = 16) patients, obtained before and 90 days after standard Sbv treatment, were probed by cELISA with NGP28b (5 ng/well). Each point represents the mean of triplicate RLU values normalized to a pool of sera from seemingly healthy NEC individuals. p Values were calculated using Wilcoxon matched-pairs test. Significance level: p < 0.05.